Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes. Issue 3 (May 2013)

• Record Type: Journal Article
• Authors: Setji, Tracy; Feinglos, Mark
• Is Part Of: Expert review of endocrinology & metabolism. Volume 8:Issue 3(2013)
• Page Start: 229
• Page End: 238
• Publication Date: 2013-05
• Subjects: albiglutide -- albugon -- diabetes mellitus -- glucagon-like peptide-1 -- glucagon-like peptide-1 receptor agonists -- obesity -- Type 2 diabetes; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1586/eem.13.2
• Languages: English
• ISSNs: 1744-6651

Abstract

Glucagon-like peptide-1 receptor agonists have become an important therapeutic option for patients with Type 2 diabetes because of their ability to lower blood glucose and help patients lose weight. There are currently three glucagon-like peptide-1 receptor agonists on the market. In the near future, albiglutide will undergo review by the US FDA for possible approval. Results from Phase I/II trials have demonstrated that albiglutide is a safe and efficacious medication for treating Type 2 diabetes. It lowers hemoglobin A1c and decreases bodyweight. It appears to have fewer gastrointestinal side effects than liraglutide. The once-weekly (or possibly longer duration) dosing of albiglutide may improve adherence. Several Phase III trials are expected to be completed in 2013. These trials will shed further light on the safety and efficacy of albiglutide.